Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in pediatric ulcerative colitis (Protocol I6T-MC-AMBU)
2019-001298-96Phase 2
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of mirikizumab in autoimmune colitis, sponsored by Eli Lilly and Company. Primary endpoints: Clearance of mirikizumab and Volume of distribution of mirikizumab.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-001298-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001298-96.